Calcitonin and vitamin D3 have high therapeutic potential for improving diabetic mandibular growth.

The goal of this study was to assess the effect of the intermittent combination of an antiresorptive agent (calcitonin) and an anabolic agent (vitamin D3) on treating the detrimental effects of Type 1 diabetes mellitus (DM) on mandibular bone formation and growth. Forty 3-week-old male Wistar rats were divided into four groups: the control group (normal rats), the control C+D group (normal rats injected with calcitonin and vitamin D3), the diabetic C+D group (diabetic rats injected with calcitonin and vitamin D3) and the diabetic group (uncontrolled diabetic rats). An experimental DM condition was induced in the male Wistar rats in the diabetic and diabetic C+D groups using a single dose of 60 mg·kg(-1) body weight of streptozotocin. Calcitonin and vitamin D3 were simultaneously injected in the rats of the control C+D and diabetic C+D groups. All rats were killed after 4 weeks, and the right mandibles were evaluated by micro-computed tomography and histomorphometric analysis. Diabetic rats showed a significant deterioration in bone quality and bone formation (diabetic group). By contrast, with the injection of calcitonin and vitamin D3, both bone parameters and bone formation significantly improved (diabetic C+D group) (P < 0.05). These findings suggest that these two hormones might potentially improve various bone properties.

Introduction

The prevalence of <span class="Disease">type 1 diabetes mellitus (DM) is considered a global health care crisis that is increasing in incidence.[1] Intensive investigations have revealed that DM has detrimental effects on various body organs and tissues, and these effects may include alterations in bone and mineral metabolism,[2,3,4] decreased bone density and increased fragility fractures, as well as poor bone healing and regeneration characteristics.[5]

Few studies have explored the effects of DM on craniofacial growth, although this field of study is of primary importance to health care professionals concerned with monitoring and treating craniofacial deficiencies, such as orthodontists and craniofacial surgeons. These studies showed that DM decreased mandibular bone formation, had a deleterious effect on osseous turnover, affected the histological integrity of the jaw bones due to alterations in the histomorphometric parameters, and affected the quality of bone structure, resulting in the stunting of its skeletal development.[1,2,3] Moreover, previous studies have shown that diabetes affects the cephalometric measurements in individuals who are still growing.[6] These results were confirmed when diabetes was introduced in growing animals and observed under strict experimental conditions, including the selection of the animals, feeding conditions and age.[2,7] Another study showed that the detrimental effects of diabetes on craniofacial growth may be induced in the foetuses of diabetic mothers.[6]

Various lines of experimental treatment have been introduced[8] to overcome the detrimental effects of DM on <span class="CellLine">bone. Among these treatments, a theoretically attractive approach was suggested that includes the intermittent administration of an anabolic agent to promote bone formation and an antiresorptive agent that would prevent further bone loss.[7,9] Evidence suggests that vitamin D3 can serve as the anabolic agent because it has a direct anabolic effect on bone and it increases the survival of osteoblasts.[9,10] In contrast, calcitonin can be used as the antiresorptive agent through its action with its specific receptors, causing powerful inhibition of osteoclast activity; moreover, its role as a regulator of calcium homeostasis that involves bone resorption is well documented.[9,11] Consequently, this may aid in improving the lines of treatment for the craniofacial growth deficiency observed in DM patients.

The hypothesis of the current study was that intermittent dosing of <span class="Chemical">vitamin D3 and <span class="Gene">calcitonin can improve the detrimental effects of DM on the internal structure and the formation process of mandibular rat bone.

Materials and methods

Animals and experimental diabetic model

Animal protocols were approved by the Institutional Animal Care and Use Committee of King Abdulaziz University, and the experiment was carried out under the control of the University's Guidelines for Animal Experimentation.

Forty 3-week-old male <span class="Species">Wistar rats were used for this study. The <span class="Species">rats were randomly divided into four groups: control group; the control group injected with calcitonin and vitamin D3 (control C+D group); the diabetic group treated with calcitonin and vitamin D3 (diabetic C+D group); and the diabetic group in which diabetes was introduced but no treatment was given (diabetic group). The rats in the control group and the control C+D group were injected with single dose of 0.1 mol·L−1 sodium citrate buffer (pH 4.5), whereas the rats in the diabetic C+D group and the diabetic group were injected intraperitoneally with a single dose of citrate buffer containing 60 mg·kg−1 body weight of streptozotocin (STZ; Sigma, St Louis, MO, USA)[12,13] to induce diabetes. Animals in all groups were fed a standard rodent diet (CE-2; Japan Clea, Shizuoka, Japan) with free access to water. Diabetes was determined in the diabetic C+D group and the diabetic group by the presence of a high level of glucose in the urine and blood, and a positive urine test and a blood glucose level of >200 mg·dL−1 were considered as DM.[2,7] The rats in the control C+D group and the diabetic C+D group were subcutaneously injected with calcitonin (Sigma, St Louis, MO, USA), which was prepared in sterile saline with a concentration of 2.0 μg·mL−1, and were dosed at with 1 mL·kg−1 body weight during the second and fourth weeks of the experiment. In addition, the rats in the control C+D group and the diabetic C+D group were injected subcutaneously with vitamin D3, 1,25-(OH)2 D3 (Cayman, Ann Arbor, MI, USA), which was prepared in ethanol (96%) and diluted in 0.15 mol·L−1 NaCl, and were dosed with 0.025 μg·kg−1 body weight[14] during the first and third weeks of the experiment.

Administration of calcein and preparation of sections

All <span class="Species">rats were injected subcutaneously with 50 mg·kg−1 body weight of a calcein fluorescent marker on 21 and 28 days after <span class="Chemical">STZ injection. At the end of the study, all animals were killed by transcardiac perfusion using 4% paraformaldehyde in 0.1 mol·L−1 phosphate buffer (pH 7.4). The right hemimandibles were dissected and fixed in the same solution. After being embedded in polystyrene resin (Rigolac; Nisshin EM, Tokyo, Japan), undemineralised ground frontal sections were processed to show the crown and both apices of the buccal and lingual roots of the lower second molar. We focused on the bone around the lower second molar because the second molar is centrally located within the mandibular arch, and the parallel alignment of the buccal and lingual roots made a precise reference when the frontal sections were produced.[7,15]

Analysis of histomorphometric indices

Histomorphometric <span class="CellLine">bone indices of the periosteal surfaces of the alveolar and the jaw <span class="CellLine">bones in all groups were evaluated using confocal laser scanning microscope (Carl Zeiss Jena, Jena, Germany) and a morphometry programme (LSM Image Browser; Carl Zeiss Jena, Jena, Germany).

The mineral apposition rate (μm·d−1) and the <span class="CellLine">bone formation rate (µm3·µm−2·d−1), as previously described by Parrafit et al.,[16] were detected in the frontal sections of the lower second molar area.

The calcein-labelled surface (<span class="Chemical">CLS; mm) was calculated as the sum of the length of double labels (dL) plus one-half of the length of single labels (sL) along the entire endosteal or periosteal bone surfaces; i.e., CLS = dL + 0.5 sL. The mineral apposition rate (MAR; µm·d−1) was determined by dividing the mean of the width of the dLs by the inter-label time (i.e., 7 days). The bone formation rate (BFR; µm3·µm−2·d−1) was calculated by multiplying the MAR by the CLS.[7] Based on the reference line along the long axis of the buccal root, the area superior to the root apex was considered to be alveolar bone, whereas the area inferior to the root apex was considered to be jaw bone. The lingual side of the mandibular bone was excluded in all specimens because of the existence of the incisor root, which may influence bone formation. The periosteal surfaces of the mandible were divided into four regions for analysis (Figure 1): region 1, alveolar crest (upper half of the tooth root, near the tooth crown); region 2, alveolar bone (lower half of the tooth root, near the root apex); region 3, buccal surface of the jaw bone; and region 4, inferior border of the jaw bone. For the measurement of the mineral apposition rate, the average of three inter-label widths at a 50-μm interval were calculated for each sample.[15]

Figure 1

Schematic of the observation regions for dynamic bone histomorphometry. The periosteal surfaces were limited to four areas: alveolar crest (region 1: upper half of the tooth root, near the tooth crown), alveolar bone (region 2: lower half of the tooth root, near the root apex), buccal surface of the jaw bone (region 3) and inferior border of the jaw bone (region 4).

Micro-computed tomography of the mandible

All left mandibles were imaged using micro-computed tomography (CT; inspeXio SMX-90CT; Shimadzu Science, Tokyo, Japan) after removing only the soft tissue. The mandibular plane was set orthogonal to the sample stage, and imaging was performed.[17] In summary, three-dimensional (3D) images of each hemimandible were acquired with a resolution voxel size of 15 μm·pixel−1. Raw data were obtained by rotating the sample stage 360°. Slice images were then prepared using multi-tomographic image reconstruction software (MultiBP; Imagescript, Tokyo, Japan). The resulting grey-scale images were segmented using a low-pass filter to remove noise and a fixed threshold to extract the mineralised bone phase. The volume of interest was drawn using a slice-based method starting from the first slice containing the crown of the first molar and moving dorsally 100 slices[18] in the area of the alveolar crest (between the buccal and lingual roots of the second molar at the cervical region) and the buccal surface of the jaw bone.[15] Trabecular bone was carefully contoured on the first and last slices, whereas the intermediate slices were first interpolated by morphing. For observation and analysis of reconstructed 3D images, we used 3D trabecular structure analysis software (TRI/3D-BON; RATOC System Engineering, Tokyo, Japan).[17] Reconstructed 3D images were prepared from slice images using the volume rendering method to analyse the microstructure of the bone. The following parameters were measured: tissue volume (TV), bone volume (BV), bone surface (BS), bone surface/bone volume (BS/BV) and bone volume fraction (BV/TV). Four properties of the trabeculae were evaluated: trabecular thickness (Tb.Th), trabecular number (Tb.N), trabecular separation (Tb.Sp) and trabecular space (Tb.S).[17,19]

Histological analysis

The left mandibles for all groups were decalcified in 10% <span class="Chemical">elhylene diaminetetraacetic acid (<span class="Chemical">EDTA) solution (pH 7.4) for 5 weeks at 4 °C.[20] The specimens were then dehydrated in an ascending ethanol series and embedded in paraffin. Serial horizontal sections (5 μm thick parallel to the occlusal plane) were prepared using a microtome (Leica RM 2155; Leica, Nussloch, Germany). Five sections were used for histochemical staining of tartrate-resistant acid phosphatase (TRAP) activity.[7] The sections were incubated for 30–60 min at 37 °C in a mixture of 0.8% naphthol AS-BI phosphate (Sigma, St Louis, MO, USA), 0.7% fast red violet salt (Sigma, St Louis, MO, USA) and 50 mmol·L−1 sodium tartrate diluted in 0.2 mol·L−1 sodium acetate buffer (pH 5.4).[7] The sections were examined under a light microscope. For the histomorphometric assessment of resorption, the number of TRAP-positive multinucleated cells (osteoclasts) on the distal surface of the alveolar bone adjacent to the mesio-buccal root of the second molar were counted in each 540 μm × 120 μm area in five consecutive sections, at the middle third of the root selected at least 25 μm from each specimen (n = 10) of each group.[7,20]

Statistical analysis

One-way analysis of variance and Tukey's post hoc test were used to compare the means of the MAR, the BFR, the <span class="CellLine">bone parameters observed by micro-CT, and the number of <span class="Gene">TRAP-positive cells recorded in all groups. All statistical analyses were performed at a 5% significance level using statistic software (v. 10; SPSS, Chicago, IL, USA).

Results

Green fluorescent lines labelled with a calcein fluorescent marker at two different time-points showed that growth took place between days 21 and 28 in all groups (Figure 2a–2d)

Figure 2

Frontal sections of the mandibular second molar area. (a) The control group; (b) the control C+D group; (c) the diabetic C+D group; (d) the diabetic group. Fluorescent labelling on the periosteal surface indicates new bone formation. (e) The changes in the MAR in regions 1–4 of the mandible among all groups. The data are expressed as the mean ± SD. n = 10 for each group. *Significant difference (P < 0.05). (f) The changes in the BFR in regions 1–4 of the mandible among all groups. The data are expressed as the mean ± SD. n = 10 for each group. *Significant difference (P < 0.05). BFR, bone formation rate; MAR, mineral apposition rate; SD, standard deviation.

The <span class="Species">rats in the <span class="Disease">diabetic group showed significant decreases in the MAR (Figure 2e) and BFR (Figure 2f) in regions 2, 3 and 4 compared with all other groups (P < 0.05). However, in the alveolar crest (region 1), the MAR and BFR results did not show any significant difference among all groups (P < 0.05). The MAR and BFR rates in regions 2, 3 and 4 in the diabetic C+D group (diabetic rats injected with calcitonin and vitamin D) showed a significant increase when compared with those of the diabetic group (P < 0.05). Moreover, there was no significant difference in the MAR and BFR between the control group and the control C+D group (normal rats injected with calcitonin and vitamin D; P < 0.05).

Micro-CT of the mandible

All trabecular parameters in both the <span class="Disease">alveolar bone and the buccal surface of the jaw bone showed significant changes (Tables 1 and 2). Compared with all groups, the alveolar bone and the buccal surface of the jaw bone in the diabetic group showed significant deteriorations in BV/TV and BS/BV. Moreover, the Tb.Th and Tb.N significantly decreased in both the alveolar and the buccal surfaces of the jaw bone in the diabetic group when compared with all other groups (P < 0.05). Correspondingly, significantly higher Tb.Sp and Tb.S were revealed in both the alveolar and the buccal surfaces of the jaw bone for the diabetic group (P < 0.05). However, the values recorded for the BV/TV, BS/BV, Tb.Th, Tb.N, Tb.Sp and Tb.S of the alveolar bone and the buccal surface of the jaw bone in the diabetic C+D group were not significantly different from the control group and the control C+D group but were significantly different from the results in the diabetic group (P < 0.05).

Table 1

Three-dimensional bone microstructure analysis of alveolar bone imaged by micro-CT and evaluated using an automated image analyser

Parameters	Control	Control C+D	Diabetic C+D	Diabetic
(Bone surface/bone volume)/mm−1	63.9 ± 15.38a	68.8 ± 4.54a	53.9 ± 7.98a	31.8 ± 9.34b
(Bone volume/tissue volume)/%	46.2 ± 1.02a	50.7 ± 2.58a	59.4 ± 3.1a	22.1 ± 11.56b
Trabecular thickness/µm	34.3 ± 4.50a	29.67 ± 1.86a	36.11 ± 6.14a	22.2 ± 1.78b
Trabecular number/mm−1	14.4 ± 2.56a	17.4 ± 1.3a	16.3 ± 2.89a	10.80 ± 1.17b
Trabecular separation/µm	25.9 ± 2.36a	28.4 ± 2.98a	23.8 ± 6.07a	40.8 ± 5.02b
Trabecular space/µm	71.18 ± 11.5 a	57.5 ± 4.01 a	62.5 ± 10.44a	87.6 ± 4.25b

micro-CT, micro-computed tomography.

P < 0.05, Same letters are statistically significant.

Table 2

Three-dimensional bone microstructure analysis of the buccal surface of jaw bone imaged by micro-CT and evaluated using an automated image analyser

Parameters	Control	Control C+D	Diabetic C+D	Diabetic
(Bone surface/bone volume)/mm−1	53.23 ± 16.11a	40.39 ± 5.17a	40.54 ± 14a	86.64 ± 4.67b
(Bone volume/tissue volume)/%	60.62 ± 13.43a	72.2 ± 2.75a	76.5 ± 16.76a	37.3 ± 4.15b
Trabecular thickness/µm	27 ± 2.00a	30.1 ± 0.53a	30.28 ± 1.15a	21.5 ± 2.82b
Trabecular number/mm−1	18.45 ± 0.17a	17.09 ± 1.22a	16.90 ± 1.04a	14.42 ± 1.9b
Trabecular separation/µm	25.9 ± 2.43a	20.2 ± 3.03a	19.9 ± 5.42a	40.9 ± 4.93b
Trabecular space (µm)	54.40 ± 0.29a	59.55 ± 2.89a	59.89 ± 3.25a	68.9 ± 7.06b

micro-CT, micro-computed tomography.

P < 0.05, Same letters are statistically significant.

<span class="CellLine">Bone resorption activity was assessed by counting the number of <span class="Gene">TRAP-positive cells on the distal surface of the alveolar bone adjacent to the mesio-buccal root of the second molar (Figure 3a–3e). The diabetic group showed a significant decrease in the number of osteoclast cells (Figure 4) when compared with the control and the control C+D groups. However, when the diabetic rats were treated with calcitonin and vitamin D3 in the diabetic C+D group, the number of the osteoclast cells was not significantly different from the number of cells observed in either the control group or the control C+D group (P < 0.05).

Figure 3

Osteoclast counts in a horizontal section of the mandibular second molar region stained with TRAP. (a) Low magnification photograph of the three roots of the second molar stained with TRAP stain. The black rectangle (540 μm × 120 μm) indicates the area on the distal surface of the alveolar bone adjacent to the middle third of the mesio-buccal root of the second molar in which the osteoclast cells were counted. (b) The mesio-buccal root of the control group (original magnification ×100). (c) The mesio-buccal root of the control C+D group (original magnification ×100). (d) The mesio-buccal root of the diabetic C+D group (original magnification ×100). (e) The mesio-buccal root of the diabetic group (original magnification ×100). (f) A schematic drawing showing the observation area on the distal surface of the alveolar bone adjacent to the mesio-buccal root of the second molar in which the osteoclast cells were counted. Bu, buccal; Di, distal; Li, lingual; Me, mesial.

Figure 4

The number of TRAP-positive cells on the distal surface of the mesio-buccal root of the mandibular second molar. Values are mean ± SD. Connected bars show the statistically significant differences among the four groups (P < 0.05), bars = 100 μm. SD, standard deviation.

Discussion

In this experiment, the intermittent dosing of <span class="Chemical">vitamin D3 and <span class="Gene">calcitonin was adopted as a means to restore the detrimental effects of DM because these two hormones act on different cellular targets and could potentially have an additive beneficial effect.[9] Previous research work has shown that the administration of vitamin D3 alone for prolonged periods or in high doses is not recommended due to the disturbances expected in calcemic activities; moreover, the application of calcitonin alone was found to be unable to restore detrimental effects on bone structure or mass caused by some systemic hormonal disturbances.[9,21]

<span class="Species">Rats between 3 and 8 weeks of age were used because this time period correspn>onds to the early growth stage in <span class="Species">humans.[2,22,23] To elaborate the mandibular bone growth changes during the short observation period adopted in the current study, the mandibular molar region was chosen. The mandibular molar exhibits remarkable eruption and has continuous root elongation along with growth, which has been reported to induce significant bone changes in these regions in growing rats.[15] A calcein fluorochrome bone marker was injected twice to determine the MAR (an indication of the osteoblastic activities at the cellular level) and the BFR (which indicates any changes in the osteoblast number and, thus, bone formation at the tissue level).[15]

The significantly lower values for MAR and BFR observed in the <span class="Disease">diabetic group agree with previous studies that recorded diminished lamellar bone formation in the femurs of DM rats and may suggest an association between DM and the decreased number and function of osteoblasts.[24,25] Moreover, DM significantly decreased the BV/TV, Tb.Th and Tb.N and significantly increased the Tb.Sp and Tb.S in the diabetic group. This agrees with other studies that have suggested that glycaemic levels play an important role in modulating the trabecular architecture, especially in mandibular bone.[5]

The histometric evaluation of <span class="Disease">diabetic <span class="Species">rats in the diabetic group confirmed the significant decrease in the number of osteoclast cells, which agrees with previous studies on the mandible[7,26] and long bones[27,28] of DM rats.

All of the aforementioned findings suggest that <span class="Disease">diabetes lead to a reduction in the rate of bone turnover. However, calcitonin and vitamin D3 improved most of the deteriorated bone parameters observed in the diabetic C+D group. Moreover, the osteoclasts cells significantly increased in the diabetic C+D group compared with the osteoclast cells in the diabetic group. These improvements observed in the diabetic C+D group may be attributed to the anabolic effect of vitamin D3 and to the antiresorptive effect of calcitonin.

The antiresorptive effect of <span class="Gene">calcitonin was previously suggested[9,10,21,29] and was considered safe and capable of stabilizing or increasing bone mineral density. In addition, calcitonin is a powerful inhibitor of osteoclast activity with only a transitory action because it is quickly eliminated from the skeleton, circulation and extravascular fluids, allowing normal remodelling to take place. Finally, calcitonin could also have mild anabolic properties as a result of cross-reactivity among bone cell receptors for calcitonin, calcitonin gene-related peptide and amylin.[30]

The major anabolic effects of <span class="Chemical">vitamin D3, which was administered to the <span class="Disease">diabetic C+D group, include stimulation of calcium absorption (intestine), enhancement of calcium reabsorption (kidney), inhibition of parathyroid hormone synthesis and secretion (parathyroid glands), and regulation of bone resorption and bone formation (skeleton).[29] Evidence suggests that vitamin D3 improves osteoblast survival and that this is the main mechanism underlying the anabolic bone effects of vitamin D3 regardless of calcium supplementation in the diet.[9]

Moreover, <span class="Chemical">vitamin D3 was previously reported[31] to increase the number of <span class="Gene">TRAP-positive cells in mice femurs; however, we hypothesise that the increase in TRAP-positive cells observed in the current experiment was not due to the direct effect of injecting the rats with vitamin D3 but rather to a general increase in the bone turnover in the diabetic C+D group. Our hypothesis is based on the following. First, the positive improvement of most of the bone parameters observed in the diabetic C+D group suggests that there was a concomitant increase in the osteoblasts along with the increase of the osteoclast cells. Second, a previous study reported that a rat model treated with calcitonin and vitamin D3 showed an increase in the osteoblast cell counts, so in the current experiment we hypothesised that there was a similar increase in the osteoblast cells, which may have expressed the nuclear factor kappa-B ligand (RANKL) that was capable of activating its osteoclasts cell receptor (RANK).[32] The stimulation of RANK induces several key regulatory transcription factors and enzymes that are essential in the promotion, differentiation, proliferation, multinucleation, activation and survival of osteoclasts,[32] which may explain the increased number of osteoclasts in the current experiment.

Furthermore, the application of <span class="Gene">calcitonin in this experiment limited the bone resorption activity exerted by the increased number of osteoclasts. This effect may be attributed to the binding of the calcitonin to specific receptors on the osteoclasts, leading to retraction of the osteoclasts from the bone surface and reduced production of acid and other proteolytic enzymes essential for the bone resorption process.[33] The effect of calcitonin ensured the diminishing of the catabolic effect exerted by the osteoclasts when compared with the anabolic effect exerted by the osteoblasts.

In conclusion, this paper suggested an important line of treatment for the stunted mandibular <span class="CellLine">bone growth problems that clinicians concerned with observing and treating <span class="Disease">craniofacial complex defects may encounter; these problems were previously clinically observed by cephalometric analysis during orthodontic treatment of patients.[6] Supplementation by antioxidants, which was previously suggested,[8] and the hormonal treatment suggested in the current study may aid in decreasing the treatment period needed to enhance mandibular growth for orthodontic young patients during the mandible growth period. In the current study, diabetes caused various deteriorations in the mandibular bone parameters, as observed by micro-CT, histomorphometric and histological examinations; however, the intermittent injection of vitamin D3 and calcitonin in diabetic rats restored most of the examined bone parameters to their normal levels. The adopted hypotheses in this study were accepted.